Skip to main content

Keratitis

2
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
1 program
1
B+L Biotrue MPS and B+L PureVisionPhase 41 trial
Active Trials
NCT01268306Completed8Est. Dec 2010
TBF Genie Tissulaire
TBF Genie TissulaireFrance - Mions
1 program
1
LV-Visio-AMTRIXPhase 21 trial
Active Trials
NCT05250583Terminated5Est. Jan 2021
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
Safety of Overnight Corneal Reshaping LensesN/A
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
Safety of Overnight Corneal Reshaping LensesN/A1 trial
Active Trials
NCT01272271Completed1,317Est. Oct 2010
Thea Pharma
Thea PharmaMA - Waltham
1 program
T4020PHASE_31 trial
Active Trials
NCT01794312CompletedEst. Dec 2017
Santen
SantenCA - Emeryville
1 program
1mg/mL ciclosporinPHASE_41 trial
Active Trials
NCT03237936Completed17Est. Jul 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Santen1mg/mL ciclosporin
AlconB+L Biotrue MPS and B+L PureVision
Thea PharmaT4020
TBF Genie TissulaireLV-Visio-AMTRIX
Bausch HealthSafety of Overnight Corneal Reshaping Lenses

Clinical Trials (5)

Total enrollment: 1,347 patients across 5 trials

NCT03237936Santen1mg/mL ciclosporin

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis

Start: Mar 2017Est. completion: Jul 201817 patients
Phase 4Completed
NCT01268306AlconB+L Biotrue MPS and B+L PureVision

Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses

Start: Oct 2010Est. completion: Dec 20108 patients
Phase 4Completed
NCT01794312Thea PharmaT4020

Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer

Start: Feb 2013Est. completion: Dec 2017
Phase 3Completed
NCT05250583TBF Genie TissulaireLV-Visio-AMTRIX

Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis

Start: Jun 2020Est. completion: Jan 20215 patients
Phase 2Terminated
NCT01272271Bausch HealthSafety of Overnight Corneal Reshaping Lenses

Safety of Overnight Corneal Reshaping Lenses

Start: Feb 2008Est. completion: Oct 20101,317 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.